EN DE

Bioptik Technology (4161) Fair Value & Analysis

Healthcare · TW · Market cap 1.4B TWD (≈ $43.3M) · ISIN TW0004161005

What is Bioptik Technology really worth?

BT Bioptik Technology 4161 · TWO
Price22.80 TWD
Fair Value20.24 TWD
Upside−11.2%
Quality52/100

A solid business, but trading 13% above our fair value of 20.24 TWD.

As of Aug 28, 2026, the fair value of Bioptik Technology is 20.24 TWD per share against a price of 22.80 TWD, so the fair value sits 11% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Bioptik Technology for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Solidly profitable · 11.9% net margin
✓Low debt · generates free cash flow
✓Ranks above peers (13/14)

Risks

!Mixed Growth (revenue 5y +11.5 %/yr)
!Moderate moat 46/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 18 out of 100

For context

·3.07% dividend yield
Evidence: Low Range 14.29 TWD – 25.29 TWD

Fair value as of: Aug 28, 2026

From 26 valuation models · updated 9 days ago

Share price +1.1% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
  • The price sits in the upper half of our model range, so the margin of safety is thin.
  • Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Price vs Fair Value (5 years)

42.60 TWD 21.60 TWD Fair Value 20.24 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.

How to read this chart

60‑month range 21.60 TWD – 42.60 TWD · fair‑value band 14.29 TWD – 25.29 TWD · the 22.80 TWD price screens above the 20.24 TWD fair value. Dashed = 300-day average. As of Aug 28, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bioptik Technology (4161) currently trades at 22.80 TWD, while our model-based Fair Value estimate is 20.24 TWD, implying the stock looks roughly 12.7% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 22.67 TWD per share, and 6 of the 26 models we run sit above the 22.80 TWD price. Bear case: the Dividend Discount group reads lowest at 3.14 TWD, and 20 of the 26 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Bioptik Technology generated revenue of 866M TWD at a net margin of 8.5%. Revenue grew 14.6% year over year. It earns a return on equity of 7.8%. Net debt stands at 68.5M TWD. Fundamentals as of Aug 28, 2026

Our scenario range runs from 14.29 TWD (bear case) to 25.29 TWD (bull case); at 22.80 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −11%, 4161 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 0.3479 TWD per share, which is 1.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence 10.58 TWD 13.03 TWD 16.24 TWD 82
Growth DCF 10.63 TWD 12.78 TWD 15.42 TWD 80
Owner Earnings 17.40 TWD 22.73 TWD 29.73 TWD 78
All 26 models by family
DCF Models
FCF DCF best evidence 10.58 TWD 13.03 TWD 16.24 TWD 82
Owner Earnings 17.40 TWD 22.73 TWD 29.73 TWD 78
5Y Revenue Exit 12.85 TWD 17.94 TWD 24.43 TWD 73
5Y EBITDA Exit 16.31 TWD 24.35 TWD 33.68 TWD 75
5Y P/E Exit 17.47 TWD 26.49 TWD 35.89 TWD 71
10Y Revenue Exit 11.58 TWD 15.72 TWD 21.21 TWD 67
10Y EBITDA Exit 13.84 TWD 19.75 TWD 27.59 TWD 69
10Y P/E Exit 14.52 TWD 21.10 TWD 29.12 TWD 64
Earnings-Based
Graham-Dodd 8.09 TWD 23.86 TWD 31.56 TWD 65
Lynch FV 5.00 TWD 7.14 TWD 9.28 TWD 61
PEG = 1.0 5.00 TWD 7.14 TWD 9.28 TWD 57
EPV 10.79 TWD 11.61 TWD 12.28 TWD 74
Dividend Discount
Gordon GGM 2.06 TWD 3.72 TWD 5.12 TWD 68
DDM Multi-Stage 2.06 TWD 3.14 TWD 3.97 TWD 67
Multiples
P/E Multiple 19.64 TWD 26.19 TWD 32.73 TWD 63
P/S Multiple 15.18 TWD 20.24 TWD 25.29 TWD 58
P/B Multiple 15.18 TWD 20.24 TWD 25.29 TWD 55
EV/EBIT 19.00 TWD 23.73 TWD 28.46 TWD 66
EV/EBITDA 22.25 TWD 28.06 TWD 33.87 TWD 67
EV/Revenue 14.94 TWD 19.28 TWD 23.62 TWD 54
Asset-Based
NCAV (Graham) 8.10 TWD 10.86 TWD 16.21 TWD 54
Growth DCF
Growth DCF 10.63 TWD 12.78 TWD 15.42 TWD 80
Rev-Margin DCF 12.85 TWD 17.92 TWD 23.63 TWD 73
Economic Profit
Residual Income 12.43 TWD 12.82 TWD 12.96 TWD 76
ROIC Compounder 10.79 TWD 11.61 TWD 12.28 TWD 72
Growth Earnings
Growth-Adj P/E 15.87 TWD 22.67 TWD 29.48 TWD 67

Widest divergence: Growth Earnings (22.67 TWD) versus Dividend Discount (3.14 TWD). Highest evidence: FCF DCF (82).

Notify me when 4161 reaches fair value

Put 4161 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 18.8
P/S ratio 1.60 P/E × margin
EPS (TTM) 1.21 TWD price ÷ EPS = P/E 18.8
Dividend yield 3.1% payout 57.9%
Net margin 8.5% FY2025
Return on equity 7.8% TTM
More key figures
Profitability
Return on assets (EBIT) 4.9% avg 5y
Operating margin 9.7% TTM
Growth
Revenue (TTM) 866M TWD TTM
Revenue growth (YoY) +14.6% 3y avg +2.9%
EPS growth (YoY) +18.4%
Balance sheet & cash flow
Free cash flow 37.2M TWD FY2025
Net debt 68.5M TWD FY2025 · ≈ 1.8 yrs of FCF

Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 52/100

Of which business quality 51 · Market factors (momentum, volatility) 45

Profitability 36
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 34
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 79
Disciplined investing over empire-building
Low Volatility 93
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 53
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally.

Full company description

Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also provides dietary supplements, such as capsules, gel capsules, tablets, solutions, powder sachet, jelly, and gummy; cosmetic products, including sunscreen, cream/lotion, make-up removal, shampoo, time capsule, and toner/essence; and skin care products. In addition, the company is involved in manufacturing feed, canned food, and food additive, aircraft and parts, and chemicals; wholesale and import and export trade of cosmetics raw materials, semi-finished products and finished products; cosmetics retail and wholesale; and special forestry management. Bioptik Technology Incorporation was founded in 1999 and is based in Zhunan, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bioptik Technology reported revenue of 837M TWD in FY2025 versus 738M TWD in FY2021, a compound +3.2%/yr. Reported net income was 71.2M TWD in FY2025, compounding +33.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Growth Quality 64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
837M TWD
Latest YoY
−3.3%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.9%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.5%
Avg. revenue growth/yr (8Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.3%
Value creation/yr (5Y, in TWD) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+37.0% · in TWD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+33.9%
Dividend yield3.1%
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−11.7% (2020) → 7.9% (2025) · rising
Worst earnings drop261% (2020) (loss year, drop beyond 100%) · in TWD
Revenue +3.2%/yr
FY21 738M TWD
FY22 768M TWD
FY23 829M TWD
FY24 865M TWD
FY25 837M TWD
Net income +33.2%/yr
FY21 22.6M TWD
FY22 48.5M TWD
FY23 85.7M TWD
FY24 93.6M TWD
FY25 71.2M TWD

4161 screens 13% overvalued. Compare with Abbott Laboratories, →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioptik Technology · Fair Value
20.24 TWD −13%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bioptik Technology Fair Value". https://www.fairvalue-calculator.com/stock/4161.TWO

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 52 · Above median
Fair Value upside −11% · Above median
Return on equity (TTM) 11% · Top 25%
Return on assets 3% · Above median
Net margin (TTM) 12% · Top 25%
Operating margin (TTM) 6% · Above median
Revenue growth 25% · Top 25%
Dividend yield (TTM) 3.1% · Above median
Debt / equity 0.12× · Higher than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 18.8× · Cheaper than median
P/B 1.41× · Cheaper than median
P/S (TTM) 1.50× · Cheaper than median
P/FCF 1.2× · Cheaper than 75% of peers
EV/EBITDA 11.0× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE18 · sector 0
FUTURE100 · sector 32
PAST45 · sector 5
HEALTH94 · sector 97
DIVIDEND61 · sector 35

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $112.47 $74.79 −34%
Stryker Corporation SYK $322.12 $186.28 −42%
Medtronic plc MDT $89.97 $65.57 −27%
Boston Scientific Corporation BSX $46.84 $30.73 −34%
Edwards Lifesciences Corporation EW $89.78 $41.02 −54%
Siemens Healthineers AG SHL €39.52 €33.87 −14%
DexCom, Inc DXCM $90.82 $38.95 −57%
GE HealthCare Technologies Inc GEHC $74.82 $64.13 −14%
Koninklijke Philips N.V PHIA €23.69 €14.36 −39%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥150.63 ¥147.63 −2%

Compare Bioptik Technology with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Bioptik Technology (4161) overvalued or undervalued?
As of Aug 28, 2026, our model estimates a fair value of 20.24 TWD versus a price of 22.80 TWD, about −11% upside (overvalued).
What is the fair value of 4161?
Our model-based fair value for Bioptik Technology is 20.24 TWD (as of Aug 28, 2026), built from audited fundamentals. The current price: 22.80 TWD.
What is the quality score of 4161?
Bioptik Technology has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioptik Technology (4161)?
Our model-based price target is the fair value of 20.24 TWD (as of Aug 28, 2026) from 26 valuation models. Cautious scenario 14.29 TWD, optimistic scenario 25.29 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioptik Technology stock forecast for 2026?
Our models put fair value at 20.24 TWD, about −11% upside versus a price of 22.80 TWD (overvalued). Cautious scenario 14.29 TWD, optimistic scenario 25.29 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Bioptik Technology (4161)?
Bioptik Technology reported trailing-twelve-month revenue of about 866M TWD (latest available figure, as of Aug 28, 2026).
What is the net profit margin of 4161?
The net profit margin of Bioptik Technology is about 8.5%, meaning it keeps roughly 8.5% of revenue as net income. Based on the latest reported figures.
Does Bioptik Technology pay a dividend?
Bioptik Technology currently shows a dividend yield of about 3.07% relative to its recent price (as of Aug 28, 2026).
Free · no account needed

Watch Bioptik Technology in the live analysis

One click puts Bioptik Technology on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.